The therapeutic results obtained in 59 patients with advanced Hodgkin's disease treated from 1964 to 1969 with sequential chemotherapy employing a single agent are reported. The main sequence was alkylating agent first, vinblastine second and procarbazine third. Complete plus partial remission (> 50 %) ranged from a minimum of 37 % for patients treated with procarbazine to a maximum of 42 % for those given vinblastine. The median duration of response ranged from 4 to 5 months. Overall median survival from institution of chemotherapy was 24 months. Patients (26 cases) responding to 2 or more drugs showed a median survival of 40 months, which was statistically greater than that observed in an equal number of cases responding only to one drug (13 months) and than that of 7 patients unresponsive to all drugs (9 months). It is concluded from this retrospective study that survival in advanced Hodgkin's disease is longer in patients responding to at least two drugs that in patients responding less or not at all.
Get full access to this article
View all access options for this article.
References
1.
AisenbergA. C., GoldmanJ. M.: Prolongation of survival in Hodgkin's disease.Cancer, 27: 802–805, 1971.
2.
BonadonnaG., MonfardiniS., OldiniC.: Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease.Europ. J. Cancer, 5: 393–402, 1969.
3.
BonadonnaG., De LenaM., BartoliC., MonfardiniS., GuzzonA., MolinariR., BajettaE., BerettaG., Fossati BellaniF., OreficeS.: Studio preliminare della fase prima della bleomicina, un nuovo farmaco antitumorale.Tumori, 57: 21–53, 1971.
4.
BonadonnaG., De LenaM., MonfardiniS., BartoliC., BajettaE., BerettaG., Fossati-BellaniF.: Clinical trials with bleomycin in lymphomas and in solid tumors.Europ. J. Cancer, 8: 205–215, 1972.
5.
BonadonnaG., MonfardiniS., De LenaM., Fossati-BellaniF., BerettaG.: Clinical trials with adriamycin. Results of a three year study. In: International Symposium on Adriamycin, p. 139–152. CarterS. K., Di MarcoA., GhioneM., KrakoffI. H., MathéG., Ed., Springer Verlag, Berlin, Heidelberg, New York, 1972.
6.
BrookJ., CockaE. F.: Comparison of single agents with combination therapy in Hodgkin's disease.Proc. Amer. Ass. Cancer Res.,13: 79, 1972.
7.
CarboneP. P., SpurrC., SchneidermanM., ScottoG., HollandJ. F., ShniderB.: Management of patients with malignant lymphoma.A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res., 28: 811–822, 1968.
8.
CarboneP. P., KaplanH. S., MusshofK., SmithersD. W., TubianaM.: Report of the committee on Hodgkin's disease staging classification.Cancer Res., 31: 1860–1861, 1971.
9.
Di PietroS.: Risultati a distanza di 100 casi di malattia di Hodgkin trattati con chemioterapia.Tumori, 53: 111–128, 1967.
10.
De LenaM., BerettaG.: Confronto dell'attività terapeutica e tossicologica fra adriamicina e bleomicina nei linfomi maligni.Tumori, 58: 7–28, 1972.
11.
De LenaM., MonfardiniS., BerettaG., Fossati-BellaniF., BonadonnaG.: Clinical trials with intensive chemotherapy and radiotherapy in Hodgkin's disease.Nat. Cancer Inst., Monogr., 36(in press).
12.
De VitaV.T., SerpickA., CarboneP.P.: Combination chemotherapy in the treatment of advanced Hodgkin's disease.Ann. Intern. Med., 73: 881–895, 1970.
13.
De VitaV.T., CarboneP.P.: Chemotherapeutic implications of staging in Hodgkin's disease.Cancer Res., 31: 1838–1844, 1971.
14.
EzdinliE. Z., StutzmanL.: Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia.J.A.M.A., 191: 444–450, 1965.
FairleyG. H., PattersonM. J. L., ScottR. B.: Chemotherapy of Hodgkin's disease with cyclophosphamide, vinblastine and procarbazine.Brit. Med. J., 2: 75–78, 1966.
17.
FlatowF. A., UltmannJ. E., HymanG. A., MuggiaF. M.: Treatment of advanced Hodgkin's disease with vinblastine or procarbazine.Cancer Chem. other. Rep., 53: 39–47, 1969.
18.
FreiE.III, De VitaV.T., MoxleyG. H.III, CarboneP.P.: Approaches to improving the chemotherapy of Hodgkin's disease.Cancer Res., 26: 1284–1289, 1966.
19.
HershE. M., FreiE.III, ColtmanC., LuceJ.: Improved combination chemotherapy (MOPP) for remission induction and maintenance in advanced Hodgkin's disease.Amer. Sociol. Clin. Oncol., 1972(Abstr. 28).
20.
JacobsB., PetersF., LuceJ. K., ZippinC., WoodD. A.: Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas.J.A.M.A., 203: 392–398, 1968.
21.
KarnofskyD. A., BurchenalJ. H.: The clinical evaluation of chemotherapeutics agents in cancer.In evaluation of chemotherapeutics agents. p. 191–205, McLeodC. M. Ed., Columbia University Press, New York, 1949.
22.
LowenbraunS., De VitaV. T., SerpickA. A.: Combination chemotherapy with nitrogen mustard, vincristine, procarbazine and prednisone in lymphosarcoma and reticulum cell sarcoma.Cancer, 25: 1018–1025, 1970.
23.
LuceJ. K., GambleJ. F., WilsonH. E., MontoR. W., IsaacsB. L., PalmerR. L., ColtmanC. A.Jr., HewlettJ. S., GehanE. A., FreiE.III: Combined cyclophosphamide, vincristine and prednisone therapy of malignant lymphomas.Cancer, 28: 306–317, 1971.
24.
RapoportA., ColeP., MasonJ.: Correlate of survival after initiation of chemotherapy in 142 cases of Hodgkin's disease.Cancer, 24: 377–381, 1969.
25.
StutzmanL., EzdinliE. Z., StutzmanM. A.: Vinblastine sulfate vs.cyclophosphamide in the therapy for lymphoma. J.A.M.A., 195: 173–178, 1966.
26.
UltmannJ. E., CunninghamJ. K., GellhornA.: The clinical picture of Hodgkin's disease.Cancer Res., 26: 1047–1061, 1966.
27.
UltmannJ. E., NixonD. D.: The therapy of lymphoma.Seminars Hemat., 6: 376–403, 1969.
